Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.
ARTICLES BY TYLER MENICHIELLO
-
![gene therapy-Adeno-associated viruses-GettyImages-597971896]( "Improving AAV Purity Upstream With PCL Manufacturing")
Improving AAV Purity Upstream With PCL Manufacturing3/21/2024The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream.
-
![goals planning 2024-GettyImages-1696762450]( "The Industry’s Positive Outlook For ADCs In 2024")
The Industry’s Positive Outlook For ADCs In 20242/26/2024Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.
-
![Copyright-FourPlus-Immersive-Ltd]( "Addressing The GMP Skills Shortage With Virtual Reality")
Addressing The GMP Skills Shortage With Virtual Reality2/14/2024In the U.K., a professor at the University of Birmingham is using virtual reality (VR) to help address the growing biomanufacturing skills shortage — using virtual reality (VR).
-
![questionaire-GettyImages-1369878082]( "Factors To Consider When Licensing An ADC Program")
Factors To Consider When Licensing An ADC Program1/30/2024Elevation Oncology's CEO and CSO explain what made the company's lead ADC candidate, EO-3021, worth licensing from Chinese pharmaceutical company, CSPC.
-
![Antibody drug conjugates ADCs GettyImages-1715913285]( "2023 ADC Roundup: A Year Of Collaboration And Licensing Deals")
2023 ADC Roundup: A Year Of Collaboration And Licensing Deals1/3/2024Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs).
-
![Developing mRNA Vaccines GettyImages-1307593959]( "RNA Vaccines: Just Scratching The Surface")
RNA Vaccines: Just Scratching The Surface12/28/2023RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.
-
![Teamwork-GettyImages-1405583619]( "How Creative Licensing Can Improve Patient Access")
How Creative Licensing Can Improve Patient Access11/16/2023Members of Caring Cross and UC Berkeley's Innovative Genomics Institute and Office of IP And Industry Research Alliances discuss the important role technology transfer offices (TTOs) play in improving ATMP accessibility. TTOs can accomplish this by designing "strings-attached" research and licensing deals upstream in product development.
-
![Gut-brain-GettyImages-1452120509]( "Targeting The Gut–Brain Axis With Live Biotherapeutic Products")
Targeting The Gut–Brain Axis With Live Biotherapeutic Products9/8/2023Treating seizures with bacteria — Bloom Science's CEO, Dr. Christopher Reyes, explains how his company aims to leverage the gut–brain axis using live biotherapeutic products (LBP).
-
![Antibody-drug-conjugated-with-cytotoxic-payload-Gettyimages-1410189307]( "ADC Advancements Allowing For Higher DAR")
ADC Advancements Allowing For Higher DAR8/22/2023A high drug-antibody-ratio (DAR) used to mean higher off-target toxicity for ADCs. Now, thanks to improvements in linker technology and antibody targeting, higher DARs can allow for improved efficacy.
-
![Isolated Antibody drug conjugates-ADCs-GettyImages-1438509824]( "How Linker Technology Is Driving ADC Development")
How Linker Technology Is Driving ADC Development8/4/2023If you’re still not excited about antibody drug conjugates (ADCs), “there’s an issue with you.” That’s the passionate, bullish sentiment (jokingly) held by Dr. Joe Daccache, project leader at DeciBio. Here, Daccache explains how innovations in linker technology are advancing the field of ADCs.
